National Institute for Clinical Excellence (NICE) Backs Roche's MabThera in Rare Autoimmune Disease
Published: Oct 03, 2013
The draft guidance overturns an earlier decision made by NICE which failed to recommend the use of MabThera (rituximab) for NHS use in England and Wales to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis – an inflammation of the blood vessels. It also comes against a series of negative NICE decisions for Roche, primarily involving its cancer drug Avastin (bevacizumab), which prompted the pharma company to challenge NICE's process to evaluate the cost-effectiveness of medicines.
Help employers find you! Check out all the jobs and post your resume.